BRIEF-Valeant and Progenics announce FDA approvals for relistor
July 19 (Reuters) - Progenics Pharmaceuticals Inc :
* Valeant expects to commence sales of relistor tablets in U.S. in Q3 of 2016
* Valeant and Progenics announce FDA approves relistor tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain
* FDA has approved relistor (methylnaltrexone bromide) tablets for treatment of opioid-induced constipation Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
© Thomson Reuters 2017 All rights reserved.